TY - JOUR
T1 - Not all IGHV3-21 chronic lymphocytic leukemias are equal
T2 - Prognostic considerations
AU - Baliakas, Panagiotis
AU - Agathangelidis, Andreas
AU - Hadzidimitriou, Anastasia
AU - Sutton, Lesley Ann
AU - Minga, Eva
AU - Tsanousa, Athina
AU - Scarfò, Lydia
AU - Davis, Zadie
AU - Yan, Xiao Jie
AU - Shanafelt, Tait
AU - Plevova, Karla
AU - Sandberg, Yorick
AU - Vojdeman, Fie Juhl
AU - Boudjogra, Myriam
AU - Tzenou, Tatiana
AU - Chatzouli, Maria
AU - Chu, Charles C.
AU - Veronese, Silvio
AU - Gardiner, Anne
AU - Mansouri, Larry
AU - Smedby, Karin E.
AU - Pedersen, Lone Bredo
AU - Moreno, Denis
AU - Van Lom, Kirsten
AU - Giudicelli, Véronique
AU - Francova, Hana Skuhrova
AU - Nguyen-Khac, Florence
AU - Panagiotidis, Panagiotis
AU - Juliusson, Gunnar
AU - Angelis, Lefteris
AU - Anagnostopoulos, Achilles
AU - Lefranc, Marie Paule
AU - Facco, Monica
AU - Trentin, Livio
AU - Catherwood, Mark
AU - Montillo, Marco
AU - Geisler, Christian H.
AU - Langerak, Anton W.
AU - Pospisilova, Sarka
AU - Chiorazzi, Nicholas
AU - Oscier, David
AU - Jelinek, Diane F.
AU - Darzentas, Nikos
AU - Belessi, Chrysoula
AU - Davi, Frederic
AU - Ghia, Paolo
AU - Rosenquist, Richard
AU - Stamatopoulos, Kostas
N1 - Publisher Copyright:
© 2015 by The American Society of Hematology 10.1182/blood-2014-09-600874.
PY - 2015/1/29
Y1 - 2015/1/29
N2 - An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
AB - An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
UR - http://www.scopus.com/inward/record.url?scp=84921856679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921856679&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-09-600874
DO - 10.1182/blood-2014-09-600874
M3 - Article
C2 - 25634617
AN - SCOPUS:84921856679
SN - 0006-4971
VL - 125
SP - 856
EP - 859
JO - Blood
JF - Blood
IS - 5
ER -